BeOne Medicines (ONC) is now covered by Wolfe Research. They set an "outperform" rating and a $340.00 price target on the stock.
BeOne Medicines (ONC) was downgraded by Jefferies Financial Group Inc. from "buy" to "hold". They now have a $290.00 price target on the stock.
BeOne Medicines Ltd (ONC) Q4 2025 Earnings Call Highlights: Record Growth and Strategic Expansion [Yahoo! Finance]
BeOne Medicines (ONC) had its price target raised by Truist Financial Corporation from $400.00 to $412.00. They now have a "buy" rating on the stock.
BeOne Medicines (ONC) had its price target raised by Guggenheim from $400.00 to $410.00. They now have a "buy" rating on the stock.